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A b s t r a c t
Deposition of  β-amyloid (Aβ), a ‘signature’ pathological lesion of Alzheimer’s disease (AD), is also characteristic of
Down’s syndrome (DS), and has been observed in dementia with Lewy bodies (DLB) and corticobasal degeneration
(CBD). To determine whether the growth of Aβ deposits was similar in these disorders, the size frequency distributions
of the diffuse (‘pre-amyloid’), primitive (‘neuritic’), and classic (‘dense-cored’) Aβ deposits were compared in AD, DS,
DLB, and CBD. All size distributions had essentially the same shape, i.e., they were unimodal and positively skewed.
Mean size of Aβ deposits, however, varied between disorders. Mean diameters of the diffuse, primitive, and classic deposits
were greatest in DS, DS and CBD, and DS, respectively, while the smallest deposits, on average, were recorded in DLB.
Although the shape of the frequency distributions was approximately log-normal, the model underestimated the fre-
quency of smaller deposits and overestimated the frequency of larger deposits in all disorders. A ‘power-law’ model
fitted the size distributions of the primitive deposits in AD, DS, and DLB, and the diffuse deposits in AD. The data sug-
gest: (1) similarities in size distributions of Aβ deposits among disorders, (2) growth of deposits varies with subtype
and disorder, (3) different factors are involved in the growth of the diffuse/primitive and classic  deposits, and (4) log-
normal and power-law models do not completely account for the size frequency distributions.
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Introduction
β-amyloid (Aβ) deposition in the form of diffuse
(‘pre-amyloid’), primitive (‘neuritic’), and classic (‘den -
se-cored’) deposits is a ‘signature’ pathological feature
of Alzheimer’s disease (AD) [4,6,9,24,28]. Aβ depo -
sition is also an important aspect of the pathology 
of Down’s syndrome (DS) due to the triplication of the
amyloid precursor protein (APP) gene on chromoso -
me 21 [15,28]. In addition, Aβ has been reported as an
additional pathology in dementia with Lewy bodies (DLB)
[18], Parkinson’s disease (PD) [50], Pick’s disease (PiD)
[50], corticobasal degeneration (CBD) [11,50], amyo -
trophic lateral sclerosis (ALS) (Hamilton and Bouser
2004), and progressive supranuclear palsy (PSP) [50].
Aβ is generated via β- and  γ-secretase cleaving of
APP resulting in the formation of an aggregated pro-
tein deposit. Three processes are involved in the forma -
tion of such deposits: (1) an initial nucleation event, 
(2) a nucleated polymerization reaction, and (3) the growth
of newly formed nuclei into larger aggregates [22,31,36].
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Several studies suggest that once initiated, Aβ deposits
in AD grow in size over time. First, pseudo colour image
processing of Aβ deposits in AD reveal gradients of den-
sity consistent with growth from a central point [21].
Second, radioiodinated human Aβ can be deposited
experimentally in vitro from a dilute solution onto pri -
mi tive and diffuse Aβ deposits causing them to grow
[38]. Third, in transgenic mice, Aβ deposits appear in
clusters which grow in size from 14 μm at 8 months
to 22 μm at 12 months [54,55]. Fourth, transgenic stud-
ies also suggest that increasing accumulation of Aβ is
largely by growth of existing deposits rather than by
further nucleation [47].
A statistical mechanics approach has been used to
model the growth of Aβ deposits in AD [52,54,55]. Two
factors have been identified that influence growth: 
(1) addition and removal of Aβ (‘aggregation/disag-
gregation’) and (2) ‘surface diffusion’ [52]. During aggre-
gation, monomers of Aβ interact to form more complex
oligomers resulting in deposit growth. During disag-
gregation, Aβ molecules are removed from a deposit
by glial cells resulting in shrinkage of a deposit. The ul -
timate size of an Aβ deposit therefore depends on 
the balance between aggregation and disaggregation. 
Surface diffusion describes a process by which addi-
tional molecular constituents are acquired by an Aβ de -
posit by diffusion through the neuropil and molecular
binding to Aβ [7,19,54,55]. Several proteins associat-
ed with Aβ deposits could have been acquired by this
process including amyloid-P, α-antichymotrypsin, com-
plement factors, and apolipoprotein E (Apo E) [9,49],
and could influence deposit growth and morphology.
The processes of aggregation/disaggregation and sur-
 face diffusion result in characteristic size frequency dis-
tributions of the resulting Aβ deposits [32,54,55].
Hence, the size frequency distribution of Aβ deposits
can be described by a ‘power-law’ model if aggrega-
tion/disaggregation predominates over surface diffu-
sion and a ‘log-normal’ model if surface diffusion is the
predominant factor [54,55]. 
The present study compared the size frequency 
distributions of Aβ deposits in the temporal lobe of four
disorders in which Aβ is deposited under different 
pathological conditions, viz., AD, DS, DLB, and CBD. 
AD and CBD are tauopathies and DLB is a synucleino -
pathy [29], while in DS, Aβ results from triplication of
the APP gene. The specific objectives were to determine:
(1) whether the size distributions were similar in dif-
ferent disorders, (2) whether the size frequency distri -
butions could be described by log-normal or power-law
models, and hence, (3) whether growth of Aβ deposits
in the various disorders could be completely explained
by aggregation/disaggregation and surface diffusion.
Material and methods
Cases
Cases (details in Table I) were obtained from the
Brain Bank, Department of Neuropathology, Institute
of Psychiatry, King’s College, London, UK. Informed con-
sent was given for the removal of all brain tissue accord-
ing to the 1996 Declaration of Helsinki (as modified
Edinburgh 2000). AD cases (N = 10) all fulfilled ‘Na-
ti onal Institute of Neurological and Communicative Dis-
orders and Stroke and the Alzheimer Disease and Relat-
ed Disorders Association’ (NINCDS/ADRDA) criteria for
probable AD [53] and neuropathologically verified using
‘Consortium to Establish a Registry of Alzheimer Dis-
ease’ (CERAD) criteria [41] and National Institute on
Aging and Reagan Institute criteria [20,33]. Clinically as -
sessed and karyotyped DS cases (N = 12) were referr -
ed from the Bethlem Royal and Maudsley Hospital and
Disorder N M : F Mean age at death; Mean disease duration;
years (range, SD) years (range, SD)
Alzheimer’s disease 10 2 : 8 80.2 (64-93, 8.5) 5.9 (2-16, 3.3)
Down’s syndrome 12 5 : 1 40.7 (38-47, 4.03) –
Dementia with 8 8 : 0 73.5 (69-77, 3.70) 7.0 (3-18, 6.0)
Lewy bodies
Corticobasal 3 1 : 2 65.5 (54-81, 10.01) –
degeneration
Table I. Demographic details of the cases used in the study
N – number of cases studied, M – male, F – female, SD – standard deviation
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St. Mary’s Hospital, London, UK [15]. DLB cases (N = 8)
were diagnosed according to the ‘Consortium on De -
mentia with Lewy bodies’ (CDLB) guidelines [40] and
possessed significant numbers of Aβ deposits. There
is no specific clinical phenotype characteristic of CBD
as diverse presentations of the disease are present [25].
However, the pathology of the cases (N = 3) was con-
sistent with the criteria recommended by the Nation-
al Institute of Health (NIH) Office of Rare Diseases 
for the pathological diagnosis of CBD [25]. First, tau-
immunoreactive neuronal cytoplasmic inclusions (NCI)
were present, glial inclusions (GI) in oligodendrocytes,
and extensive inclusions within the processes or
‘threads’ of astrocytes (‘astrocytic plaques’). Second,
NCI and GI were present in the white and grey mat-
ter of various cortical regions and in the striatum. Third,
neuronal loss was present in focal cortical areas and
in the substantia nigra.
Histological methods
A block of the temporal cortex was taken from each
case at the level of the lateral geniculate nucleus to
study the superior temporal gyrus (B22), inferior tem-
poral gyrus (B20), and parahippocampal gyrus (B28),
regions which have high densities of Aβ deposits in the
disorders studied [10,11,15,18]. Tissue was fixed in 10%
phosphate buffered formal-saline and embedded in
paraffin wax. 7 μm coronal sections were stained with
a rabbit polyclonal antibody (Gift of Prof. B.H. Ander-
ton, Institute of Psychiatry, King’s College London) raised
to the 12-28 amino acid sequence of the Aβ protein [51].
The antibody was used at a dilution of 1 in 1200 and
the sections incubated at 4°C overnight. Sections were
pretreated with 98% formic acid for 6 minutes which
enhances Aβ immunoreactivity. Aβ was visualised using
the streptavidin-biotin horseradish peroxidase proce-
dure with diaminobenzidine as the chromogen. Sec-
tions were also stained with haematoxylin. 
Morphometric methods
In each gyrus studied, the greatest diameters of
a sample of diffuse, primitive, and classic Aβ deposits
were measured. Guidelines were marked on the slide
parallel to the pia mater to sample laminae II/III and
V/VI, which contain the most significant numbers of
deposits [2]. The maximum diameter of each Aβ deposit
touching a guideline was then measured at a magnifi -
cation of ×400 using an eyepiece micrometer. The three
most common morphological subtypes of Aβ deposit
were identified using previously defined criteria [4,24].
Hence, diffuse Aβ deposits were 10-200 μm in diam-
eter, irregular in shape, had diffuse boundaries, and
were lightly immunolabelled. Large confluent patch-
es of Aβ immunolabelling, which could be a variant of
diffuse deposit, were not quantified. Primitive deposits
were 20-60 μm, well demarcated, more symmetrical
in shape than diffuse deposits, and strongly immuno-
labelled and may be analogous to the neuritic plaques
(NP), the predominant type of plaque in AD [26,27].
Classic deposits were 20-100 μm, had a distinct cen-
tral ‘core’ surrounded by a ‘corona’ of dystrophic neu-
rites. Within a disorder, there were no significant diffe -
rences in size distributions between cases and brain
regions within a case. Hence, to obtain a sufficiently
large sample of each Aβ deposit type of each disorder
for analysis, measurements were pooled from all
brain regions and cases.
Data analysis
Two statistical models were fitted to the data using
STATISTICA software (Statsoft Inc., 2300 East 14th St,
Tulsa, OK74104, USA). First, a ‘power-law’ model was
fitted to each size distribution. A variable (Y) is dis-
tributed as a power-law function of X if the depend-
ent variable has an exponent ‘a’, i.e., a function of the
form Y = CX–a. If the data are fitted by such a function,
a plot of log (Y) against log (X) should yield a linear rela-
tionship. Hence, for each region, deposit sizes were
grouped into classes and the logarithm of the frequency
of the deposits in each class was plotted against the
logarithm of the upper size limit of the class. A linear
function was then fitted to the data and the goodness
of fit to a linear model tested using Pearson’s corre-
lation coefficient (‘r’). Second, a log-normal model was
fitted to the size distribution of each type of deposit
from each disorder. This distribution is defined as that
of a variable X such that the natural logarithm (ln) of
(X – ∅) is normally distributed [45]. The distribution has
three parameters: ∅ (where X > ∅), the mean (μ), and
the variance (σ2). In many applications, the value of ∅
can be assumed to be zero and a two-parameter mo -
del fitted to the data. Deviations from a log-normal
model were tested using the Kolmogorov-Smirnov (KS)
goodness of fit test. Size frequency distributions were
compared between disorders using chi-square (χ2) 
contingency table tests. In addition, mean diameters
of each type of deposit were compared among disor-
ders using one-way analysis of variance (ANOVA) and
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Fisher’s protected least significant difference (PLSD)
as a post-hoc procedure [13].
Results
The size distributions of the diffuse, primitive, and clas-
sic Aβ deposits in each disorder are shown in Figs. 1-3.
The distributions, regardless of subtype or disorder, had
similar shapes, i.e., they were unimodal and exhibit-
ed a significant degree of positive skew. There were
few Aβ deposits in the smallest size classes, maximum
frequency occurred within a single size class (the modal
class), and the frequency of the larger deposits de clined
with increasing size. The mean size, modal class, stan-
dard deviation (SD), and degree of skew of the size dis-
tributions of Aβ deposits in AD, DS, DLB, and CBD are
shown in Table II. Diffuse Aβ deposits were on aver-
age larger than the primitive and classic deposits 
and exhibited the greatest degree of skew. The primi -
tive A  deposits were often the smallest deposits pre -
sent. The mean diameters of the diffuse (F = 282.83, 
P < 0.001), primitive (F = 97.20, P < 0.001), and clas-
sic (F = 15.47, P < 0.001) varied among disorders. The
mean diameter of the diffuse Aβ deposits was great-
est in DS and least in DLB while the mean diameter
of the primitive deposits was greatest in DS and CBD
and least in DLB. The mean diameter of the classic 
Aβ deposits was greatest in DS and least in CBD.
The size frequency distributions of the diffuse, prim-
itive, and classic Aβ deposits in the four disorders are
shown in Figs. 1-3. There were significant differences
in size frequency distribution among disorders for all
deposit types: (1) DS had a significantly higher proportion
of larger diffuse deposits and DLB a higher proportion
of smaller diffuse deposits than either AD or CBD, which
had similar size distributions of diffuse deposits (Fig. 1),
(2) DS had the highest proportion of larger primitive
deposits, followed by CBD, AD, and DLB (Fig. 2), the prim-
itive deposits in AD having a particularly restricted size
range, and (3) classic deposits reached their greatest
size in DS, followed by AD, with DLB and CBD having
a higher proportion of smaller classic deposits. 
The result of fitting a log-normal distribution to the
diffuse Aβ deposits in AD is shown in Figure 4. The dis-
tribution is approximately log-normal in shape but also
deviates significantly from the model in some size class-
es (KS = 0.16, P < 0.01). Hence, the frequency of the
Fig. 1. Size frequency distributions of the diffuse  β-amyloid (Aβ in four neurodegenerative disorders. Chi-square
(χ2) contingency table analysis comparing disorders: AD/DS χ2 = 194.23 (13 DF, P < 0.001), DS/DLB χ2 = 695.12
(13 DF, P < 0.001), DLB/CBD χ2 = 112.58 (13 DF, P < 0.001), AD/DLB χ2 = 193.46 (13 DF, P < 0.001), DS/CBD 
χ2 = 93.66 (13 DF, P < 0.001, AD/CBD χ2 = 11.81 (13 DF, P > 0.05).
AD – Alzheimer’s disease, DS – Down’s syndrome, DLB – dementia with Lewy bodies, CBD – corticobasal degeneration
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Fig. 2. Size frequency distributions of the primitive β-amyloid (Aβ in four neurodegenerative disorders. 
Chi-square (χ2) contingency table analysis comparing disorders: AD/DS χ2 = 62.10 (10 DF, P < 0.001), DS/DLB 
χ2= 8.9 (10 DF, P < 0.001), DLB/CBD χ2 = 122.74 (7 DF, P < 0.001), AD/DLB χ2 = 163.26 (9 DF, P < 0.001), DS/CBD
χ2 = 14.61 (7 DF, P < 0.05), AD/CBD χ2 = 25.25 (7 DF, P < 0.001).
Fig. 3. Size frequency distributions of the classic β-amyloid (Aβ in four neurodegenerative disorders. 
Chi-square (χ2) contingency table analysis comparing disorders: AD/DS χ2= 4.20 (11 DF, P < 0.05), DS/DLB 
χ2 = 22.80 (9 DF, P < 0.01), DLB/CBD χ2 = 3.74 (9 DF, P > 0.05), AD/DLB χ2 = 13.06 (10 DF, P > 0.05), DS/CBD
χ2= 51.54 (9 DF, P < 0.001), AD/CBD χ2 = 32.08 (9 DF, P < 0.001).
AD – Alzheimer’s disease, DS – Down’s syndrome, DLB – dementia with Lewy bodies, CBD – corticobasal degeneration
AD          DS          DLB          CBD
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smaller Aβ deposits was greater than predicted by 
the model, there were more deposits than expected
in the modal class, and there were fewer deposits than
expected in the larger size classes. Goodness-of-fit 
of the log-normal distribution to all disorders and 
Aβ subtypes is shown in Table III. Size distributions,
regardless of subtype or disorder, exhibited a similar
pattern of deviation from a log-normal distribution, the
model underestimating the frequency of smaller de -
posits and overestimating the frequency of larger de -
posits.
An example of fitting a power-law model to the size
distributions of the primitive Aβ deposits in DLB is
shown in Figure 5. There is a statistically significant
fit to this model (r = –0.86, P < 0.01). Nevertheless, the
data also depart from a power-law model, viz., there
were fewer Aβ deposits than predicted in the smallest
size classes, more than expected in the intermediate
size classes, and fewer in the largest size classes. A sig-
nificant fit to a power-law model was obtained for 5/12
(42%) of the size distribution studied, viz., the pri -
mitive deposits in AD, DS, and DLB and the diffuse
deposits in AD. All size distributions, however, exhib-
ited similar departures from a power-law model, the
model overestimating the frequency of the smallest
and largest deposits.
Fig. 4. Goodness of fit of the size frequency dis-
tribution of the diffuse β-amyloid (Aβ) deposits in
Alzheimer’s disease (AD) to a ‘log-normal’ model.
Deviation from model: KS = 0.16, P < 0.01. 
Group Deposit N Mean Mode Median SD Skew
type (μm) (μm) (mm) (μm)
AD Diffuse 715 47.22 50 45 20.01 1.20**
Primitive 796 31.58 30 30 11.76 0.65*
Classic 888 37.02 30 35 14.52 0.88**
DS Diffuse 898 64.34 50 60 27.89 1.03**
Primitive 2177 35.29 30 30 15.80 0.97*
Classic 302 40.52 30 40 16.36 1.26**
DLB Diffuse 1340 36.56 30 30 18.35 1.62**
Primitive 921 25.74 20 20 13.18 1.38*
Classic 338 35.65 30 30 15.83 0.98**
CBD Diffuse 285 49.28 40 45 23.07 1.41**
Primitive 326 32.60 30 30 12.44 0.41**
Classic 149 14.90 20 25 13.59 0.86**
Table II. Summary statistics for the size frequency distributions of the diffuse, primitive, and classic  β-amyloid
(Aβ) deposits in four neurodegenerative disorders 
AD – Alzheimer’s disease, DS – Down’s syndrome, DLB – dementia with Lewy bodies, CBD – corticobasal degeneration
N – number of deposits sampled, SD – standard deviation
*P < 0.05, **P < 0.01
Analysis of variance (ANOVA): One-way with ‘Fisher’s protected least significant difference’ (PLSD) post-hoc procedure: Diffuse Aβ  deposits F = 282.83 
(P < 0.001), DS > CBD = AD > DLB; Primitive Aβ deposits F = 97.20 (P < 0.001), DS = CBD > AD > DLB; Classic Aβ deposits F = 15.47 (P < 0.001), DS > AD = DLB > CBD
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Discussion
There are two problems in estimating the size dis-
tributions of Aβ deposits which exist in three dimen-
sions (3D) measured in a single plane. First, sampling
in two dimensions (2D) underestimates the frequen-
cy of the smaller deposits and overestimates the fre-
quency of the larger deposits [16,34]. Second, the sec-
tion cuts through different portions of the deposit, i.e.,
some small diameter measurements represent sections
taken through the peripheral portions of larger-sized
deposits [14]. The absolute density of deposits in each
size class in 3D can be calculated from their size dis-
tribution in 2D using matrix algebra if it is assumed that
the deposits are spherical and randomly distributed
[23,48,56]. However, this method is not appropriate for
Aβ deposits, because although many deposits may be
approximately spherical, they are not randomly dis-
tributed but occur in distinct clusters [10,12]. The effect
of sampling in 2D on the size frequency distributions
of Aβ deposits has been studied in AD [16]. Using data
from a sample of brain regions, the size distributions
of Aβ deposits in single sections were compared with
their distribution in a volume of tissue by serial re con-
struction through the tissue. The data suggested that
the two sources of bias cancel out and that therefore,
the errors involved in estimating the size distribution
of protein aggregates in 3D by 2D sampling are rela-
tively small [16].
All size frequency distributions, regardless of mor-
phological subtype or disorder, were asymmetric and
positively skewed similar to previous reports of Aβ de -
Disorder Subtype Deviation from Fit to power-law
log-normal model (KS) model (‘r’)
AD Diffuse 0.16** –0.61*
Primitive 0.17** –0.77**
Classic 0.14 ** –0.56 ns
DS Diffuse 0.13** –0.59 ns
Primitive 0.17** –0.68**
Classic 0.14** –0.57 ns
DLB Diffuse 0.11** –0.41 ns
Primitive 0.15** –0.86**
Classic 0.15 ** –0.57 ns
CBD Diffuse 0.14 ** –0.42 ns
Primitive 0.18** –0.49 ns
Classic 0.12* –0.57 ns
Table III. Size class frequency distributions of diffuse, primitive, and classic β-amyloid (Aβ) deposits in var-
ious neurodegenerative disorders
AD – Alzheimer’s disease, DS – Down’s syndrome, DLB – dementia with Lewy bodies, CBD – corticobasal degeneration
Goodness of fit to log-normal and power-law models: KS – Kolmogorov-Smirnov statistic, ‘r’ – Pearson’s correlation coefficient
*P < 0.05, **P < 0.01, ns – not significant
Fig. 5. Goodness of fit of the size frequency dis-
tribution of the primitive β-amyloid (Aβ) de po -
sits in Down’s syndrome (DS) to a ‘power-law’
model. Fit to model: r = –0.86, P < 0.01. 
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
–0.5
0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2
Log (size classes)
Lo
g 
(F
re
qu
en
cy
)
Richard A. Armstrong
Folia Neuropathologica 2012; 50/3 247
posits in AD [8,32]. These results suggest similarities
in the growth of Aβ deposits in the different disorders.
Nevertheless, there were differences among disorders
including in mean diameter, degree of skew, and in
length of the tail of the distribution. The largest dif-
fuse and classic deposits occurred in DS, while the 
diffuse and primitive deposits in DLB and classic de -
posits in CBD exhibited the least growth potential. In
DS, deposits may grow more rapidly or develop over
a much longer time period compared with the other
disorders. First, Aβ deposition in DS is associated with
triplication of the APP gene, which may result in over-
production of Aβ and therefore, faster-growing and
larger deposits. Second, virtually all patients with DS
develop Aβ deposits if they survive into their thirties
[15,39,43,57], with particular accumulations of deposits
observed between the ages of 30 and 50 years [32].
Hence, Aβ deposits in DS may develop over longer peri-
ods than in AD, DLB, and CBD. The smallest deposits
were observed in DLB and CBD. The rate of progres-
sion of disease may be faster in these disorders than
in AD or DS resulting in less time for deposit growth
[44]. Alternatively, Aβ deposition in DLB and CBD could
be related to the onset of dementia which may occur
later in parkinsonian syndromes than in AD or DS [46]. 
Development of Aβ deposits is influenced by at least
two processes, viz., aggregation/disaggregation of Aβ
and surface diffusion followed by molecular binding
to Aβ [52,54,55]. In all four disorders, although size 
distributions approximated to a log-normal distribution,
they also deviated from the model, Aβ deposits ap pear-
ing to grow less in all disorders than predicted. Vari-
ous factors could restrict growth of an Aβ deposit. 
For example, growth could be limited by the lack or
insufficient quantity of a suitable ‘chaperone’ molecule
[35,37], inhibited diffusion of the molecule through the
neuropil, failure of the molecule to penetrate sufficiently
into an Aβ deposit, or failure to bind to Aβ [17].
A power-law model fitted the size distributions of
the diffuse and primitive Aβ deposits in AD and the
primitive deposits in DS and DLB. In AD and DS, dif-
fuse deposits are spatially correlated with neuronal cell
bodies [1,5,42]. Development of diffuse deposits may
therefore involve: (1) secretion of Aβ monomers from
clusters of adjacent neuronal perikarya, (2) association
of Aβ monomers to form more complex oligomers, and
(3) formation of an aggregated deposit [5,21]. Further
condensation of the deposit and its association with
neuritic pathology, in the form of dystrophic neuritis
(DN), may then result in the formation of a primitive-
type Aβ deposit [4]. Disaggregation within a deposit
may also occur as a result of the removal of Aβ mo -
nomers by glial cells which are frequently embedded
within and present at the periphery of many diffuse
and primitive deposits [17]. Nevertheless, some size dis-
tributions, most notably those of the classic Aβ deposits
in all disorders and all deposit subtypes in CBD, were
not fitted successfully by a power-law model suggest -
ing additional factors were involved in growth. Classic
deposits are frequently spatially associated with
blood vessels, and substances diffusing from blood 
vessels may influence growth [3,7]. In addition, CBD 
is a four-repeat (4R) tauopathy with extensive neuritic
degeneration in the form of NCI, GI, and astrocytic
plaques [25]. Hence, in CBD, there may be a greater
chance that a diffuse Aβ deposit will combine with neu-
ritic elements to form a primitive deposit.
In conclusion, the shape of the size frequency dis-
tributions of diffuse, primitive, and classic Aβ deposits
show considerable similarities in AD, DS, DLB, and CBD.
Nevertheless, Aβ deposits exhibit differences in growth
potential between disorders, diffuse and classic de posits
in DS exhibiting the greatest growth and diffuse de -
posits in DLB and classic deposits in CBD the least
growth. Although both aggregation/disaggregation and
surface diffusion may play a role in deposit growth, all
size distributions deviated to some extent from pre-
viously described models suggesting additional factors
must be involved.
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